Modulation of secretory factors by lipofundin contributes to its anti‑neuroinflammatory effects

Chen,Ming-Shan; Hu,Chia-Lin; Jiang,Shin-Kuang; Chong,Zhi-Yong; Chen,Jui-Chieh

doi:10.3892/etm.2024.12456

Modulation of secretory factors by lipofundin contributes to its anti‑neuroinflammatory effects

Authors:
- Ming-Shan Chen
- Chia-Lin Hu
- Shin-Kuang Jiang
- Zhi-Yong Chong
- Jui-Chieh Chen
View Affiliations

Affiliations: Department of Anesthesiology, Ditmanson Medical Foundation Chia‑Yi Christian Hospital, Chiayi 60002, Taiwan, R.O.C., Department of Neurology, China Medical University Hospital, Taichung 404332, Taiwan, R.O.C., Department of Biochemical Science and Technology, National Chiayi University, Chiayi 600355, Taiwan, R.O.C.
Published online on: February 27, 2024 https://doi.org/10.3892/etm.2024.12456
Article Number: 169
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As the global population ages, the prevalence of neuroinflammatory diseases such as Alzheimer's disease, Parkinson's disease and stroke continues to increase. Therefore, it is necessary to develop preventive and therapeutic methods against neuroinflammatory diseases. Lipofundin is a lipid emulsion commonly used in clinical anesthetic solvents and nutritional supplements. Lipid emulsions have been shown to possess anti‑inflammatory properties. However, the potential beneficial effect of lipofundin against neuroinflammation requires elucidation. In the present study, two cell models were used to investigate the efficacy of lipofundin against neuroinflammation. In the first model, BV2 mouse microglial cells were treated with lipopolysaccharide (LPS) to induce nitric oxide (NO) production as a model of neuroinflammation. In the second model, HMC3 human microglial were activated by LPS, and changes in the secretion of factors associated with inflammation were analyzed using Luminex xMAP^® technology. Griess assay results revealed that lipofundin significantly prevented and treated LPS‑induced NO production. An anti‑neuroinflammatory effect was also observed in HMC3 cells, where lipofundin exhibited excellent preventive and therapeutic properties by reducing the LPS‑induced expression and secretion of interleukin‑1β. Notably, lipofundin also promoted the secretion of certain growth factors, suggesting a potential neuroprotective effect. These results demonstrate that, in addition to its role as a solvent for drugs and nutritional support, lipofundin may also have beneficial effects in alleviating the progression of neuroinflammation. These findings may serve as an important reference for future translational medicine applications.

View Figures

View References

1	Kaur G, Han SJ, Yang I and Crane C: Microglia and central nervous system immunity. Neurosurg Clin N Am. 21:43–51. 2010.PubMed/NCBI View Article : Google Scholar
2	Spiteri AG, Wishart CL, Pamphlett R, Locatelli G and King NJC: Microglia and monocytes in inflammatory CNS disease: Integrating phenotype and function. Acta Neuropathol. 143:179–224. 2022.PubMed/NCBI View Article : Google Scholar
3	Muzio L, Viotti A and Martino G: Microglia in neuroinflammation and neurodegeneration: From understanding to therapy. Front Neurosci. 15(742065)2021.PubMed/NCBI View Article : Google Scholar
4	Qiu M, Xu E and Zhan L: Epigenetic regulations of microglia/macrophage polarization in ischemic stroke. Front Mol Neurosci. 14(697416)2021.PubMed/NCBI View Article : Google Scholar
5	Scheiblich H, Trombly M, Ramirez A and Heneka MT: Neuroimmune Connections in Aging and Neurodegenerative Diseases. Trends Immunol. 41:300–312. 2020.PubMed/NCBI View Article : Google Scholar
6	Chen MS, Yang KS, Lin WC, Fang CL, Chen HF and Sheu SM: Lipofundin mediates major inhibition of intravenous propofol on phorbol myristate acetate and Escherichia coli-induced neutrophil extracellular traps. Mol Biol Rep. 9:6517–6529. 2022.PubMed/NCBI View Article : Google Scholar
7	Chen MS, Tung YW, Hu CL, Chang HJ, Lin W and Sheu SM: Three lipid emulsions reduce staphylococcus aureus-stimulated phagocytosis in mouse RAW264.7 cells. Microorganisms. 9(2479)2021.PubMed/NCBI View Article : Google Scholar
8	Chen MS, Lu PK, Lin WC, Shin HC, Sie SR and Sheu SM: Lipofundin mediates the major inhibition of intravenous propofol in IL-1β secretion and phagocytosis of staphylococcus aureus-infected macrophages. Lipids. 55:45–52. 2020.PubMed/NCBI View Article : Google Scholar
9	Daniels MJ and Brough D: Unconventional pathways of secretion contribute to inflammation. Int J Mol Sci. 18(102)2017.PubMed/NCBI View Article : Google Scholar
10	Turner MD, Nedjai B, Hurst T and Pennington DJ: Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta. 1843:2563–2582. 2014.PubMed/NCBI View Article : Google Scholar
11	Baker HN, Murphy R, Lopez E and Garcia C: Conversion of a capture ELISA to a Luminex xMAP assay using a multiplex antibody screening method. J Vis Exp. 4084:2012.PubMed/NCBI View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
13	Lo J, Liu CC, Li YS, Lee PY, Liu PL, Wu PC, Lin TC, Chen CS, Chiu CC, Lai YH, et al: Punicalagin Attenuates LPS-Induced Inflammation and ROS Production in Microglia by Inhibiting the MAPK/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. J Inflamm Res. 15:5347–5359. 2022.PubMed/NCBI View Article : Google Scholar
14	Vinnars E and Wilmore D: Jonathan roads symposium papers. History of parenteral nutrition. JPEN J Parenter Enteral Nutr. 27:225–231. 2003.PubMed/NCBI View Article : Google Scholar
15	Williams JJ, Mayurasakorn K, Vannucci SJ, Mastropietro C, Bazan NG, Ten VS and Deckelbaum RJ: N-3 fatty acid rich triglyceride emulsions are neuroprotective after cerebral hypoxic-ischemic injury in neonatal mice. PLoS One. 8(e56233)2013.PubMed/NCBI View Article : Google Scholar
16	Berressem D, Koch K, Franke N, Klein J and Eckert GP: Intravenous treatment with a long-chain omega-3 lipid emulsion provides neuroprotection in a murine model of ischemic stroke - a pilot study. PLoS One. 11(e0167329)2016.PubMed/NCBI View Article : Google Scholar
17	Tanioka M, Park WK, Park J, Lee JE and Lee BH: Lipid emulsion improves functional recovery in an animal model of stroke. Int J Mol Sci. 21(7373)2020.PubMed/NCBI View Article : Google Scholar
18	Zendedel A, Habib P, Dang J, Lammerding L, Hoffmann S, Beyer C and Slowik A: Omega-3 polyunsaturated fatty acids ameliorate neuroinflammation and mitigate ischemic stroke damage through interactions with astrocytes and microglia. J Neuroimmunol. 278:200–211. 2015.PubMed/NCBI View Article : Google Scholar
19	Chen X, Wu S, Chen C, Xie B, Fang Z, Hu W, Chen J, Fu H and He H: Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-κB pathway following experimental traumatic brain injury. J Neuroinflammation. 14(143)2017.PubMed/NCBI View Article : Google Scholar
20	Baazm M, Behrens V, Beyer C, Nikoubashman O and Zendedel A: Regulation of inflammasomes by application of omega-3 polyunsaturated fatty acids in a spinal cord injury model. Cells. 10(3147)2021.PubMed/NCBI View Article : Google Scholar
21	Zhao T, Ma D, Mulati A, Zhao B, Liu F and Liu X: Development of astaxanthin-loaded layer-by-layer emulsions: physicochemical properties and improvement of LPS-induced neuroinflammation in mice. Food Funct. 12:5333–5350. 2021.PubMed/NCBI View Article : Google Scholar
22	Della Giustina A, Goldim MP, Danielski LG, Florentino D, Garbossa L, Joaquim L, Oliveira Junior AN, Mathias K, Fileti ME, Zarbato GF, et al: Fish oil-rich lipid emulsion modulates neuroinflammation and prevents long-term cognitive dysfunction after sepsis. Nutrition. 70(110417)2020.PubMed/NCBI View Article : Google Scholar
23	Li P and Song C: Potential treatment of Parkinson's disease with omega-3 polyunsaturated fatty acids. Nutr Neurosci. 25:180–191. 2022.PubMed/NCBI View Article : Google Scholar
24	Wen YT, Huang TL, Huang SP, Chang CH and Tsai RK: Early applications of granulocyte colony-stimulating factor (G-CSF) can stabilize the blood-optic-nerve barrier and ameliorate inflammation in a rat model of anterior ischemic optic neuropathy (rAION). Dis Model Mech. 9:1193–1202. 2016.PubMed/NCBI View Article : Google Scholar
25	Wen Q, Kong Y, Zhao HY, Zhang YY, Han TT, Wang Y, Xu LP, Zhang XH and Huang XJ: G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 54:1419–1433. 2019.PubMed/NCBI View Article : Google Scholar
26	Rasouli B, Ghahari L, Safari M, Shahroozian E and Naeimi S: Combination therapy of the granulocyte colony stimulating factor and intravenous lipid emulsion protect the hippocampus after global ischemia in rat: focusing on CA1 region. Metab Brain Dis. 35:991–997. 2020.PubMed/NCBI View Article : Google Scholar
27	Schäbitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Schölzke MN, Sommer C and Schwab S: Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke. 34:745–751. 2003.PubMed/NCBI View Article : Google Scholar
28	England TJ, Gibson CL and Bath PM: Granulocyte-colony stimulating factor in experimental stroke and its effects on infarct size and functional outcome: A systematic review. Brain Res Rev. 62:71–82. 2009.PubMed/NCBI View Article : Google Scholar
29	Popa-Wagner A, Stöcker K, Balseanu AT, Rogalewski A, Diederich K, Minnerup J, Margaritescu C and Schäbitz WR: Effects of granulocyte-colony stimulating factor after stroke in aged rats. Stroke. 41:1027–1031. 2010.PubMed/NCBI View Article : Google Scholar